A playbook with 37 detailed analyses for a pharmaceutical company
Each analysis includes:
- Goal of the analysis
- Data required
- Detailed step-by-step instruction on how to conduct the analysis
- Format of the output of analysis
- How to interpret results
- Steps a company can take to improve on the measure
In this guide you'll learn the following 37 analyses across seven categories:
Table of Contents
A. RESEARCH & DEVELOPMENT
- Drug Pipeline Analysis
- Clinical Trial Success Rates
- Preclinical Research Productivity
- Pharmacokinetics and Pharmacodynamics (PK/PD) Profile Analysis
- Pipeline Attrition Rate and Risk Mitigation
- Accelerated Approval Pathway Utilization
- Companion Diagnostics Integration
- Adaptive Clinical Trial Design Strategy
- Breakthrough Therapy Designation Utilization
B. REGULATORY & COMPLIANCE
- Regulatory Pathway Complexity
- Regulatory Risk for Off-Label Drug Use
- Compliance with Good Manufacturing Practices (GMP)
- International Regulatory Harmonization and Compliance Strategy
- Drug Price Transparency and Regulatory Compliance
- Pediatric Exclusivity and Extensions
C. OPERATIONS & SUPPLY CHAIN
- Supply Chain and Cold Chain Logistics Evaluation
- Biosimilars Threat Assessment
- Specialty Drug Delivery Systems and Technologies
- Expanded Access Program Impact
- Compassionate Use Program Strategy
D. MARKETING & MARKET ACCESS
- Pricing Power and Reimbursement Environment
- Pharmaceutical Market Access and Health Technology Assessment (HTA) Outcomes
- Real-World Evidence (RWE) Integration for Drug Development
- Therapeutic Area Specialization and Competitive Position
- Global Drug Launch Strategy and Sequencing
- Rare Disease Market Penetration
- Drug Pricing Regulation Across Emerging Markets
- Healthcare Provider (HCP) Engagement and Influence Strategy
E. LICENSING & PARTNERSHIPS
- Licensing and Partnership Agreements
- Early-Stage Compound Licensing Opportunities
- Generics Portfolio Strength and Market Share
F. SALES & COMMERCIALIZATION
- Pharmaceutical Sales Force Effectiveness
- Specialty Pharmacy Channel Strategy
G. FINANCIAL ANALYSIS
- Intellectual Property (IP) Portfolio and Patent Expiry Risk
- Market Exclusivity Periods for Key Drugs
- Pharmacoeconomic Impact Studies
- Drug-Drug Interaction (DDI) Risk Management